Terranova R, Gilotta S M, Luca S
Institute of Clinical Gerontology and Geriatrics, University of Catania, Italy.
Arzneimittelforschung. 1997 Nov;47(11A):1325-8.
Depression and distress have in common hypercortisolism, a high turn-over of cerebral monoamines and a wide clinical variability. Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported. Oral treatment with 1800 mg pivagabine lasting 30 days showed in both groups a significant improvement of the psychic state with variations from 50 to 80% of the criteria reported in the Hamilton Rating Scale for Depression (HDRS) and for anxiety (HARS) and in the Self-rating Anxiety Scale (SAS). Good tolerance of the drug and the complete absence of serious side effects considerably contributed to the clinical success.
抑郁症和精神困扰都存在高皮质醇血症、脑单胺高周转率以及广泛的临床变异性。本文报告了一项关于匹伐加宾（4 - [(2,2 - 二甲基 - 1 - 氧代丙基)氨基]丁酸，CAS 69542 - 93 - 4，Tonerg）的临床开放试验结果，该试验针对22名患有心境恶劣障碍的年轻患者以及38名在经历不同应激源（哀悼、退休和在救助机构康复）后患有适应障碍的老年患者。持续30天口服1800毫克匹伐加宾的治疗在两组中均显示出精神状态的显著改善，汉密尔顿抑郁量表（HDRS）、汉密尔顿焦虑量表（HARS）以及自评焦虑量表（SAS）所报告标准的改善幅度在50%至80%之间。药物的良好耐受性以及完全没有严重副作用对临床疗效有很大贡献。
